TACSTD2 and non-small cell lung carcinoma: This pooled analysis aims to assess the survival and safety outcomes of the trophoblast cell-surface antigen 2-directed antibody–drug conjugates (ADCs) sacituzumab govitecan and datopotamab deruxtecan compared to docetaxel in pre-treated patients with advanced/metastatic non-small cell lung cancer by integrating data from the randomized phase III trials EVOKE-01 and TROPION-Lung01.